Trial Profile

Clinical proof-of-concept study with OXP 003 [Safestat™ Atorvastatin]

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 07 May 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary)
Indications Hyperlipidaemia
Focus Adverse reactions

Most Recent Events

07 May 2014 Study title not official; phase assumed. Exact indication unclear.
07 May 2014 New trial record
30 Apr 2014 Oxford Pharmascience has reviewed its proposed initial clinical development programme for OXP 003 with the Medicines and Healthcare Products Regulatory Agency and has appointed Quotient Clinical to conduct the proof-of-concept study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com